Carbamazepine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Carbamazepine: From Epilepsy and Trigeminal Neuralgia to Trigeminal Nerve Neoplasm
One-Sentence Summary
Carbamazepine is a sodium-channel-blocking anticonvulsant, established for epilepsy and trigeminal neuralgia. The TxGNN model predicts it may be useful for trigeminal nerve neoplasm, but the evidence is thin: 1 clinical trial (an imaging study that does not test carbamazepine) and 20 publications, mostly case reports of tumors that present as trigeminal neuralgia. Any benefit would most likely be pain control, not an anti-tumor effect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy and trigeminal neuralgia (general established use; the license records in the pack contain no indication text) |
| Predicted New Indication | Trigeminal nerve neoplasm |
| TxGNN Prediction Score | 99.998% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 licenses (the five listed are ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Carbamazepine blocks voltage-gated sodium channels. This is the basis of its use in trigeminal neuralgia, a condition the drug is well established for. Detailed mechanism-of-action data are not available in the record, so this description comes from the repurposing rationale only.
The prediction most likely reflects the link between trigeminal neuralgia and tumors of the trigeminal nerve or nearby structures. Trigeminal neuralgia can be caused by a tumor, and many of the retrieved papers describe tumors that first appeared as trigeminal neuralgia. Examples are lymphoma, schwannoma, meningioma, epidermoid cyst and lipoma. In these reports carbamazepine was used for the pain, not to treat the tumor.
The relationship is therefore symptomatic (neuropathic pain control), not oncologic. Nothing in the evidence shows an anti-neoplastic effect. The only indirect support is a 1988 rat study, in which carbamazepine reduced spontaneous activity in experimental neuromas.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06853119 | N/A | Not yet recruiting | 120 | MRI study of brain network and structural changes in trigeminal neuralgia. It involves no neoplasm population and no carbamazepine intervention (relevance grade C). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36824641 | 2022 | Review | Acta Clin Croat | Treatment options for trigeminal neuralgia. It notes the pain can be caused by vascular compression or a tumor. |
| 17997704 | 2007 | Review | Expert Rev Neurother | Overview of medical and surgical treatments for trigeminal neuralgia. |
| 3181365 | 1988 | Preclinical | Exp Neurol | Intravenous carbamazepine inhibited spontaneous activity in experimental rat neuromas. |
| 30741017 | 2023 | Case report | Br J Neurosurg | Primary lymphoma of the trigeminal nerve with facial pain. Carbamazepine did not improve symptoms. |
| 25142539 | 2014 | Case report | Rinsho Shinkeigaku | Lymphoma spreading along the trigeminal nerve. Pain initially improved on carbamazepine, then stopped responding. |
| 25433061 | 2014 | Case report | No Shinkei Geka | Trigeminal neuralgia from a cerebellopontine angle lipoma. Carbamazepine control was inadequate because of side effects. |
| 33989821 | 2021 | Case report | World Neurosurg | Petroclival meningioma causing trigeminal neuralgia, treated surgically. |
| 26768887 | 2016 | Case report | Turk Neurosurg | Pituitary adenoma presenting as isolated trigeminal neuralgia. |
| 25968963 | 2015 | Case report | World Neurosurg | Trigeminal neuralgia caused by a venous angioma, with literature review. |
| 19184299 | 2009 | Case report | Odontology | Trigeminal neuralgia secondary to a cerebellopontine angle epidermoid cyst. |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA205571 | Carbamazepine (Northstar Rx LLC) | Tablet, extended release | Not provided in the record |
| ANDA219939 | Carbamazepine (Alembic Pharmaceuticals Limited) | Tablet, film coated, extended release | Not provided in the record |
| ANDA078986 | Carbamazepine (Major Pharmaceuticals) | Capsule, extended release | Not provided in the record |
| ANDA216193 | Carbamazepine (Ajanta Pharma USA Inc.) | Tablet, extended release | Not provided in the record |
| ANDA075687 | Carbamazepine (Sun Pharmaceutical Industries, Inc.) | Tablet, chewable | Not provided in the record |
All listed products are oral.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The high TxGNN score most likely reflects the trigeminal neuralgia link, not an anti-tumor effect. The only registered trial is an imaging study that does not test carbamazepine, and the literature is mostly case reports in which carbamazepine was used for pain. Carbamazepine’s role here would be symptom control for tumor-associated neuralgia, which is already covered by its established use.
To proceed, the following is needed:
- Package insert warnings and contraindications, which are missing from the record.
- Mechanism-of-action data from DrugBank.
- Evidence of carbamazepine efficacy in tumor-associated trigeminal pain, such as a cohort study or trial, or a clear decision that this is a symptomatic-use question only.
- Review of the other high-scoring predictions, which are reflex epilepsy subtypes (for example thinking seizures and reading seizures). They fit carbamazepine’s existing antiseizure mechanism better but lack indication-specific evidence.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.